S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

NLS Pharmaceutics (NLSP) News Today

$0.40
-0.01 (-2.44%)
(As of 02/23/2024 ET)
SourceHeadline
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
finanznachrichten.de - February 23 at 8:59 AM
seekingalpha.com logoNLSP NLS Pharmaceutics Ltd.
seekingalpha.com - February 14 at 8:27 AM
finance.yahoo.com logoNotice of Deficiency with Nasdaq Continued Listing Requirements
finance.yahoo.com - January 20 at 10:29 AM
finanznachrichten.de logoNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing Requirements
finanznachrichten.de - January 12 at 7:41 PM
benzinga.com logoNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider Trades
benzinga.com - December 23 at 9:37 AM
morningstar.com logoNLS Pharmaceutics Ltd Ordinary Shares
morningstar.com - December 21 at 7:40 PM
benzinga.com logoNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and Dates
benzinga.com - December 5 at 7:23 AM
finance.yahoo.com logoNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
finance.yahoo.com - December 1 at 8:10 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
finanznachrichten.de - November 27 at 10:28 AM
morningstar.com logoNLS Pharmaceutics Ltd Ordinary Shares NLSP
morningstar.com - November 21 at 8:26 PM
msn.com logoWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% Today
msn.com - November 16 at 1:11 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
finance.yahoo.com - November 16 at 8:11 AM
finance.yahoo.com logoNLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
finance.yahoo.com - October 19 at 5:52 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic Partnerships
finanznachrichten.de - October 12 at 1:16 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Company Update on Strategic Partnerships
finance.yahoo.com - October 12 at 1:16 PM
msn.com logoNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95
msn.com - October 5 at 6:41 PM
msn.com logoMaxim Group Downgrades NLS Pharmaceutics (NLSP)
msn.com - September 14 at 5:40 PM
benzinga.com logoNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder Letter
benzinga.com - August 28 at 2:28 PM
finance.yahoo.com logoNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
finance.yahoo.com - July 3 at 12:00 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Company Update and Webcast Today Postponed
finanznachrichten.de - July 2 at 9:49 AM
finance.yahoo.com logoNLS Pharmaceutics Releases the Results from its Annual General Meeting
finance.yahoo.com - June 30 at 8:27 PM
finance.yahoo.com logoNLS Pharmaceutics Company Update and Webcast Today Postponed
finance.yahoo.com - June 30 at 10:20 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update Webcast
finanznachrichten.de - June 19 at 8:04 AM
finance.yahoo.com logoCORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
finance.yahoo.com - June 19 at 8:04 AM
markets.businessinsider.com logoNLS Pharmaceutics (NLSP) Receives a Buy from Maxim Group
markets.businessinsider.com - June 15 at 5:00 PM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
finanznachrichten.de - June 15 at 12:00 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Company Update Webcast
finance.yahoo.com - June 15 at 12:00 PM
finance.yahoo.com logoNLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
finance.yahoo.com - June 15 at 12:00 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
finance.yahoo.com - June 14 at 10:22 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
finanznachrichten.de - May 8 at 11:19 AM
msn.com logoNLS Pharmaceutics appoints Keith Harrison Dewedoff as interim CFO; stock slumps ~13%
msn.com - May 8 at 11:19 AM
finance.yahoo.com logoNLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
finance.yahoo.com - May 8 at 11:19 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
finanznachrichten.de - May 4 at 10:31 AM
markets.businessinsider.com logoAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE) and NLS Pharmaceutics (NLSP)
markets.businessinsider.com - May 4 at 10:31 AM
finance.yahoo.com logoNLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
finance.yahoo.com - May 4 at 10:31 AM
finance.yahoo.com logoNLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
finance.yahoo.com - May 2 at 9:49 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
finanznachrichten.de - April 25 at 10:57 AM
finance.yahoo.com logoNLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
finance.yahoo.com - April 25 at 10:57 AM
marketbeat.com logoWhy Did Bullfrog AI Stock Jump More Than 50%? (NLSP)
marketbeat.com - April 5 at 7:01 AM
markets.businessinsider.com logoMaxim Group Sticks to Their Buy Rating for NLS Pharmaceutics (NLSP)
markets.businessinsider.com - March 28 at 7:14 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
finance.yahoo.com - March 27 at 9:40 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics to Present at the 35th Annual Roth Conference
finanznachrichten.de - March 1 at 8:55 AM
finance.yahoo.com logoNLS Pharmaceutics to Present at the 35th Annual Roth Conference
finance.yahoo.com - March 1 at 8:55 AM
markets.businessinsider.com logoMaxim Group Keeps Their Buy Rating on NLS Pharmaceutics (NLSP)
markets.businessinsider.com - January 31 at 1:11 PM
finance.yahoo.com logoNLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
finance.yahoo.com - January 30 at 10:59 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
finanznachrichten.de - January 25 at 8:47 AM
finance.yahoo.com logoNLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
finance.yahoo.com - January 25 at 8:47 AM
finance.yahoo.com logoNLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
finance.yahoo.com - January 23 at 9:40 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
finanznachrichten.de - January 12 at 9:04 AM
finanznachrichten.de logoNLS Pharmaceutics AG: NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
finanznachrichten.de - January 12 at 9:04 AM
Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.



NLSP Media Mentions By Week

NLSP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NLSP
News Sentiment

0.00

0.45

Average
Medical
News Sentiment

NLSP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NLSP Articles
This Week

1

0

NLSP Articles
Average Week

Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:NLSP) was last updated on 2/23/2024 by MarketBeat.com Staff